IL15 and metastatic malignant neoplasm: Infusion of IL-15 (2 μg/kg/d) into metastatic cancer patients led to greater than 350-fold expansion of CD56bright NK cells that had enhanced tumor recognition, cytokine production, and cytotoxic activity [22].